40 completed, 7 terminated, 5 recruiting, 5 withdrawn. 60 Phase 2, 9 Phase 3, 8 Phase 1.
Follow CSL Behring: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) Anumigilimab, Placebo - Sickle Cell Disease | Phase 2 | Recruiting | CSL Behring | 63 | 2026-02-02 | 2026-08-05 |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | Active not recruiting | CSL Behring | 84 | 2026-01-22 | 2026-10-21 |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787, Placebo, Nebulizer - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | CSL Behring | 180 | 2025-09-03 | 2026-10-19 |
| Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis CSL889, Placebo - Sickle Cell Disease Vaso-occlusive Crisis | Phase 2 | Recruiting | CSL Behring | 70 | 2025-07-10 | 2026-10-08 |
| Zemaira Eosinophilic Esophagitis Pilot Study Alpha-proteinase inhibitor - Eosinophilic Esophagitis | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 15 | 2025-05-15 | 2025-12-17 |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) CSL300, Placebo - End Stage Kidney Disease | Phase 2 / Phase 3 | Recruiting | CSL Behring | 3110 | 2024-04-27 | 2026-09-21 |
| Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study Clazakizumab, Placebo - Inflammation, Frailty | Phase 2 | Completed | Anne B. Newman | 29 | 2023-08-01 | 2026-06-11 |
| Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis Garadacimab, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | CSL Behring | 81 | 2022-02-03 | 2024-12-13 |
| A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH) fibrinogen concentrate, Placebo - Postpartum Hemorrhage | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-01-01 | 2021-03-15 | |
| Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease CSL346, Placebo - Diabetic Kidney Disease (DKD) | Phase 2 | Completed | CSL Behring | 114 | 2020-09-14 | 2023-12-06 |
| CSL324 in COVID-19 CSL324, Placebo - Coronavirus Disease 2019 (COVID-19) | Phase 2 | Withdrawn | CSL Behring | 2020-09-01 | 2020-10-14 | |
| Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo - Coronavirus Disease 2019 (COVID-19) | Phase 2 | Completed | CSL Behring | 124 | 2020-07-01 | 2022-01-24 |
| Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Clazakizumab, Placebo - COVID-19 | Phase 2 | Terminated | Columbia University | 1 | 2020-05-18 | 2022-04-08 |
| A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line CSL312, Placebo - PICC-associated Thrombosis | Phase 1 / Phase 2 | Withdrawn | CSL Behring | 2020-03-01 | 2020-03-25 | |
| Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro10, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Withdrawn | CSL Behring | 2019-12-20 | 2020-11-17 | |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | CSL Behring | 27 | 2019-09-19 | 2024-02-05 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | CSL Behring | 222 | 2019-03-27 | 2026-09-09 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
| A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Factor XIIa antagonist monoclonal antibody, Placebo - Hereditary Angioedema | Phase 2 | Completed | CSL Behring | 44 | 2018-10-29 | 2022-11-08 |
| Dose Confirmation Trial of AAV5-hFIXco-Padua AAV5-hFIXco-Padua (AMT-061) - Hemophilia B | Phase 2 | Completed | CSL Behring | 3 | 2018-07-24 | 2024-06-28 |
Showing 20 of 60. Sign in to see all of them.
Hemophilia B (5) · Hemorrhage (4) · Arthritis, Rheumatoid (3) · COVID-19 (3) · Hemophilia A (3) · Anemia, Sickle Cell (2) · Angioedemas, Hereditary (2) · Coronary Artery Disease (2) · Inflammation (2) · Scleroderma, Diffuse (2) · Vaso-Occlusive Crises (2) · Acquired Immunodeficiency Syndrome (1) · Acute Chest Syndrome (1) · Acute Kidney Injury (1) · Afibrinogenemia (1)
clazakizumab (12) · Fibrinogen (7) · Sodium Chloride (7) · Saline Solution (5) · alpha 1-Antitrypsin (5) · Factor VIII (4) · Complement C1 Inhibitor Protein (3) · Immunoglobulins, Intravenous (3) · gamma-Globulins (3) · Albumins (2) · Hizentra (2) · albutrepenonacog alfa (2) · von Willebrand Factor (2) · Adalimumab (1) · CSL112 (1)
United States (35) · Germany (20) · Canada (18) · Italy (18) · Australia (15) · Poland (15) · United Kingdom (14) · Spain (13) · Austria (10) · France (10) · Netherlands (10) · Russia (10) · Hungary (9) · Israel (9) · Czechia (8)
Anders Perner, Professor (1) · Anne B. Newman, MD, MPH (1) · Arno P Nierich, MD, PhD. (1) · Bernd Jilma, MD (1) · Bernd Kieseier, MD (1) · Christopher Denton, PhD (1) · Cynthia L Bristow, PhD (1) · Danielle Duffy, MD (1) · David J. Cohen, MD (1) · Dr. Denise D'Andrea (1)
PMID 33217027, PMID 40386832, PMID 19767078, PMID 19804533, PMID 20624109, PMID 20674826, PMID 21649849, PMID 21692906, PMID 23249928, PMID 23410777, PMID 23718572, PMID 23987198, PMID 24229737, PMID 25458735, PMID 25606785, PMID 26016741, PMID 26138593, PMID 26755710, PMID 27059799, PMID 27330001, PMID 27399982, PMID 27430210, PMID 27659879, PMID 27881559, PMID 28241354, PMID 28421246, PMID 29246900, PMID 29437593, PMID 30116551, PMID 30580130, PMID 30635033, PMID 30965011, PMID 31698454, PMID 31824943, PMID 31916575, PMID 34153143, PMID 34887657, PMID 35219377, PMID 36326435, PMID 36382130, PMID 36490302, PMID 36994730, PMID 37000214, PMID 38710185, PMID 38796655, PMID 39150859, PMID 39341368, PMID 39909490, PMID 40188458, PMID 41518612
2014 (3), 2018 (3), 2009 (2), 2015 (2), 2025 (2), 2004 (1), 2008 (1), 2017 (1), 2019 (1)